title: Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel.
abstract: OBJECTIVE
  To develop evidence-based guidelines for (1) prostate re-biopsy after radiation and (2) radiation therapy with rising prostate-specific antigen (PSA) levels after radical prostatectomy in the management of patients with localized prostatic cancer.
  
  
  METHODS
  The American Society of Therapeutic Radiology and Oncology (ASTRO) challenged a multidisciplinary consensus panel to address consensus on specific issues in each of the two topics. Four well-analyzed patient data sets were presented for review and questioning by the panel. The panel sought criteria that would be valid for patients in standard clinical practice as well as for patients enrolled in clinical trials. Subsequent to an executive session that followed these presentations, the panel presented its consensus guidelines.
  
  
  CONCLUSIONS
  Based on the data presented, the prostate re-biopsy negative rates ranged from 62% to 80% for patients with stage T1-2 tumors. The panel judged that prostate re-biopsy is not necessary as standard follow-up care and that the absence of a rising PSA level after radiation therapy is the most rigorous end point of total tumor eradication. Further, the panel judged that re-biopsy may be an important research tool. Based on the data presented, the long-term (5 years or more) PSA remission rate after salvage radiation therapy ranges from 27% to 45%. The panel requested results from prospective randomized trials to evaluate optimally this information. The panel judged that the total dose of radiation should be 64 Gy or slightly higher and that, in patients with or without radiation therapy, there is no standard role for androgen suppressant therapy for rising PSA values after prostatectomy.
authors.affiliation: American Society for Therapeutic Radiology and Oncology, Reston, VA, USA.
authors.forename: J D
authors.initials: JD
authors.lastname: Cox
authors.forename: M J
authors.initials: MJ
authors.lastname: Gallagher
authors.forename: E H
authors.initials: EH
authors.lastname: Hammond
authors.forename: R S
authors.initials: RS
authors.lastname: Kaplan
authors.forename: P F
authors.initials: PF
authors.lastname: Schellhammer
mesh_terms: D001706:Biopsy; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000032:analysis*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D011879:Radiotherapy Dosage; D019233:Retreatment
chemical_list: D017430:Prostate-Specific Antigen